Florian Lüke

856 total citations
29 papers, 356 citations indexed

About

Florian Lüke is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Florian Lüke has authored 29 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Florian Lüke's work include CAR-T cell therapy research (4 papers), Brain Metastases and Treatment (3 papers) and Cancer Genomics and Diagnostics (3 papers). Florian Lüke is often cited by papers focused on CAR-T cell therapy research (4 papers), Brain Metastases and Treatment (3 papers) and Cancer Genomics and Diagnostics (3 papers). Florian Lüke collaborates with scholars based in Germany, Italy and Austria. Florian Lüke's co-authors include Tobias Pukrop, Daniel Heudobler, Albrecht Reichle, Wolfgang Herr, Martin Vogelhuber, Lina Ghibelli, Christopher Gerner, Kathrin Weidele, Christoph A. Klein and Anke Schlenska‐Lange and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Florian Lüke

26 papers receiving 355 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Florian Lüke Germany	10	171	97	75	70	58	29	356
Nisha Durand United States	11	208 1.2×	102 1.1×	45 0.6×	74 1.1×	126 2.2×	24	488
Vidya Bodempudi United States	13	212 1.2×	94 1.0×	181 2.4×	79 1.1×	45 0.8×	14	466
Matthew Genet United States	12	240 1.4×	133 1.4×	95 1.3×	100 1.4×	92 1.6×	20	498
Gunnhildur Ásta Traustadóttir Iceland	13	281 1.6×	132 1.4×	27 0.4×	66 0.9×	34 0.6×	23	446
Catharina Conrad Germany	11	190 1.1×	209 2.2×	82 1.1×	106 1.5×	52 0.9×	18	501
Daniel Xia United States	10	264 1.5×	72 0.7×	70 0.9×	112 1.6×	203 3.5×	29	529
Frederick D. Park United States	5	227 1.3×	82 0.8×	39 0.5×	50 0.7×	21 0.4×	5	349
Yan Yi China	15	261 1.5×	153 1.6×	55 0.7×	61 0.9×	34 0.6×	35	584
Ganga Gopinathan United Kingdom	5	169 1.0×	140 1.4×	30 0.4×	69 1.0×	28 0.5×	9	393
J. Vogt United Kingdom	6	399 2.3×	110 1.1×	41 0.5×	45 0.6×	37 0.6×	6	532

Countries citing papers authored by Florian Lüke

Since Specialization

Citations

This map shows the geographic impact of Florian Lüke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florian Lüke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florian Lüke more than expected).

Fields of papers citing papers by Florian Lüke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florian Lüke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florian Lüke. The network helps show where Florian Lüke may publish in the future.

Co-authorship network of co-authors of Florian Lüke

This figure shows the co-authorship network connecting the top 25 collaborators of Florian Lüke. A scholar is included among the top collaborators of Florian Lüke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florian Lüke. Florian Lüke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harrer, Dennis Christoph, Florian Lüke, Tobias Pukrop, Albrecht Reichle, & Daniel Heudobler. (2026). Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic Acid. International Journal of Molecular Sciences. 27(2). 1067–1067.

Proescholdt, Martin, Karl-Michael Schebesch, Christian Doenitz, et al.. (2025). MetInfilt: A prospective trial highlighting the importance of the histological growth pattern in brain metastases. Translational Oncology. 60. 102480–102480. 1 indexed citations

Harrer, Dennis Christoph, Florian Lüke, Tobias Pukrop, et al.. (2025). MEPED as salvage therapy for relapsed/refractory Hodgkin’s lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck. Frontiers in Pharmacology. 16. 1553331–1553331. 1 indexed citations

Heudobler, Daniel, Céline Schulz, Jens Hoffmann, et al.. (2025). 658O Nivolumab, ipilimumab and bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamous NSCLC and untreated brain metastases (CA209-7WF/Break B5-BM-NSCLC/AIO-TRK-0220/ass). Annals of Oncology. 36. S453–S454.

Harrer, Dennis Christoph, Florian Lüke, Tobias Pukrop, et al.. (2024). Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity. Frontiers in Oncology. 13. 1289222–1289222. 3 indexed citations

Harrer, Dennis Christoph, Florian Lüke, Tobias Pukrop, et al.. (2023). Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance. Cancers. 16(1). 180–180. 5 indexed citations

Fante, Matthias, Dennis Christoph Harrer, Florian Lüke, et al.. (2023). All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma. Frontiers in Oncology. 13. 1177330–1177330. 2 indexed citations

Scheiter, Alexander, Felix Keil, Cédric Coulouarn, et al.. (2022). Wnt/β-Catenin-Pathway Alterations and Homologous Recombination Deficiency in Cholangiocarcinoma Cell Lines and Clinical Samples: Towards Specific Vulnerabilities. Journal of Personalized Medicine. 12(8). 1270–1270. 3 indexed citations

Lüke, Florian, Dennis Christoph Harrer, Pan Pantziarka, et al.. (2022). Drug Repurposing by Tumor Tissue Editing. Frontiers in Oncology. 12. 900985–900985. 7 indexed citations

10.

Harrer, Dennis Christoph, Florian Lüke, Ingo Einspieler, et al.. (2022). Case Report: Extramedullary Acute Promyelocytic Leukemia: An Unusual Case and Mini-Review of the Literature. Frontiers in Oncology. 12. 886436–886436.

11.

Scheiter, Alexander, Florian Lüke, Felix Keil, et al.. (2021). STRN-ALKFusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy. JCO Precision Oncology. 5(5). 1507–1513. 4 indexed citations

12.

Lüke, Florian, Dennis Christoph Harrer, Karin Menhart, et al.. (2021). Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease. Frontiers in Pharmacology. 12. 599561–599561. 11 indexed citations

13.

Heudobler, Daniel, Christian Schulz, Jürgen R. Fischer, et al.. (2021). A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). Frontiers in Pharmacology. 12. 599598–599598. 9 indexed citations

14.

Lüke, Florian, Dennis Christoph Harrer, J. Hahn, et al.. (2021). Continuous Complete Remission in Two Patients with Acute Lymphoblastic Leukemia and Severe Fungal Infection Following Short-Term, Dose-Reduced Chemotherapy. Frontiers in Pharmacology. 12. 599552–599552. 2 indexed citations

15.

Fehlmann, Tobias, Christian Werno, Kathrin Weidele, et al.. (2021). Single-cell microRNA sequencing method comparison and application to cell lines and circulating lung tumor cells. Nature Communications. 12(1). 4316–4316. 61 indexed citations

16.

Lüke, Florian, Evelyn Orsó, Hendrik Poeck, et al.. (2020). Coronavirus disease 2019 induces multi‐lineage, morphologic changes in peripheral blood cells. SHILAP Revista de lepidopterología. 1(1). 376–383. 21 indexed citations

17.

Heudobler, Daniel, Florian Lüke, Martin Vogelhuber, et al.. (2019). Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue—Going Beyond Apoptosis Induction. Frontiers in Oncology. 9. 1408–1408. 15 indexed citations

18.

Heudobler, Daniel, Peter Staib, Thomas Wehler, et al.. (2019). Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non-small cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung). Annals of Oncology. 30. v646–v647. 3 indexed citations

19.

Heudobler, Daniel, Florian Lüke, Martin Vogelhuber, et al.. (2018). Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis. Frontiers in Pharmacology. 9. 1357–1357. 18 indexed citations

20.

Weiss, Ingrid M., et al.. (2013). On the function of chitin synthase extracellular domains in biomineralization. Journal of Structural Biology. 183(2). 216–225. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact